Voacamine
CAS No. : 3371-85-5
| Size | Price | Stock |
|---|---|---|
| 1mg | $160 | In-stock |
| 5mg | $336 | In-stock |
| 10mg | $571 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N6932 |
| M.Wt: | 704.90 |
| Formula: | C43H52N4O5 |
| Purity: | >98 % |
| Solubility: |
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer[1][2][3][4][5].
In Vitro:Voacamine (1.4 μM) induces a slight increase in the apoptotic fraction of 23.6% in A2780 cells[2].
Voacamine (Compound VOA) (0-18 μM, 24-48 h) has antiproliferative activities against breast cancer cell lines (MCF-7 and 4T1)[3].
Voacamine (0-10 μM, 24-48 h) has anti-migratory and proapoptotic effect on MCF-7 and 4T1 cells[3].
Voacamine (1.5-5 μM) significantly diminishes the G0/G1 and G2/M phase of MCF-7 and 4T1 cells[3].
Voacamine (2.5-9 μM) collapses MMP and induces ROS production in MCF-7 and 4T1 cells[3].
Voacamine (0-8 μM) induces inhibition of p-PI3K/p-Akt/p-mTOR pathway and interacts with PI3K protein via molecular docking simulation[3].
Voacamine (1-10 μM, 24-72 h) results in a dose- and time-dependent reduction in the cell survival in U-2 osteosarcoma cells[4].
Voacamine (5 μM, 24 h) shows a higher number of cells in G1 phase than control and abundant formation of autophagosomes in U-2 osteosarcoma cells[4].
Voacamine (0-10 μM, 24-48 h) substantially restrains the viability of CRC cell lines (CT26 and HCT116) [5].
Voacamine (0-10 μM) induces apoptisis via EGFR/PI3K/Akt signaling pathway in CT26 and HCT116 cells[5].
In Vivo:Voacamine (Compound VOA) (15-30 mg/kg, s.c., single dose) results in a significant reduction in the tumor volume and weight in BALB/c mice with 4T1 cells induced xenograft tumor[3].
Voacamine (15-30 mg/kg, i.p., 2 w) suppresses the progression of xenograft colorectal tumor in BALB/c mice injected with CT26 cells[5].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Voacamine
- Cat. No.:
- HY-N6932
- Quantity:
Your information is safe with us.